Specialized sarcoma centers enhance coordinated care for young adults, although travel and financial barriers persist, Dr. Vinayak Venkataraman stated.
Dr. Vinayak Venkataraman
Advertisement
He currently serves as the director of Sarcoma Pathways and is a physician at Dana-Farber Cancer Institute, in Boston, Massachusetts, where is also an instructor in medicine and an affiliated faculty at the McGraw/Patterson Center for Population Sciences, Harvard Medical School.
Articles by Dr. Vinayak Venkataraman
Emerging investigational agents may shift the current standard of care for patients with the rare sarcoma known as gastrointestinal stromal tumor (GIST).
Advertisement
Latest Updated Articles
New Directions in Treatment for Patients With GISTPublished: October 30th 2025 | Updated:
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Komzifti for NPM1-Mutant Acute Myeloid Leukemia
2
Cancer Experts Share Emerging Treatments Patients Should Know in 2026
3
FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer
4
Experts Highlight Notable Advances in Colorectal Cancer at 2025 ESMO
5
